Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

This study tests whether adding ganagliflozin tablets to standard treatment can slow the worsening of kidney disease in people with type 2 diabetes. About 1,244 adults with both conditions will be randomly assigned to receive either the drug or a placebo for 120 weeks. The main g…

This study tests a new medicine called HDM1005 against an existing drug, mazdutide, in about 900 adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone or with another diabetes pill. The goal is to see which drug works better at lowering blood sug…

This early-phase study looks at how a single shot of HDM1005 moves through the body in people with reduced kidney function compared to healthy volunteers. About 30 overweight or obese adults aged 18-75 will take part. The goal is to understand safety and drug levels, not to treat…

This early-stage study looks at how a new drug called HDM1005 affects stomach emptying and interacts with common medications like metformin, atorvastatin, warfarin, and digoxin in 42 overweight or obese Chinese adults aged 18-45. The goal is to understand how the body processes t…